Detalhe da pesquisa
1.
Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction.
Blood
; 137(1): 20-28, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33410896
2.
High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
Pediatr Blood Cancer
; 70(1): e29990, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36250996
3.
Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
Blood
; 135(17): 1458-1466, 2020 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32027741
4.
Reverse-engineering flow-cytometry gating strategies for phenotypic labelling and high-performance cell sorting.
Bioinformatics
; 35(2): 301-308, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29931307
5.
Closing the circle for ETP ALL.
Blood
; 142(24): 2039-2040, 2023 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38095922
6.
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Blood
; 129(25): 3304-3313, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28389462
7.
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
Nature
; 481(7380): 157-63, 2012 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-22237106
8.
Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
J Formos Med Assoc
; 116(10): 774-781, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28063722
9.
Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
Blood
; 124(7): 1081-8, 2014 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-25006133
10.
Expanded and armed natural killer cells for cancer treatment.
Cytotherapy
; 18(11): 1422-1434, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27497701
11.
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Lancet Oncol
; 16(4): 465-74, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25800893
12.
Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.
Br J Haematol
; 168(1): 94-101, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25164427
13.
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Cancer
; 120(10): 1514-9, 2014 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24501014
14.
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.
Blood
; 120(26): 5173-80, 2012 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-23074282
15.
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.
Blood
; 120(2): 468-72, 2012 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22517895
16.
Should evaluation for minimal residual disease be routine in acute myeloid leukemia?
Curr Opin Hematol
; 20(2): 86-92, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23380603
17.
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
Cancer
; 119(22): 4036-43, 2013 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24006085
18.
Agammaglobulinemia associated with BCRâ» B cells and enhanced expression of CD19.
Blood
; 118(7): 1828-37, 2011 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-21693761
19.
New markers for minimal residual disease detection in acute lymphoblastic leukemia.
Blood
; 117(23): 6267-76, 2011 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-21487112
20.
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.
Blood
; 118(2): 223-30, 2011 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-21613256